Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  topotecan hydrochloride
Find trials that include:  Any drugs shown
Results 1-22 of 22 for your search:
Start Over
Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: GOG-0281, NCI-2014-00629, NCT02101788
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-GY005, NCI-2015-00651, NCT02502266
Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 50 and under
Trial IDs: AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC0861, NCI-2011-00312, 09-000742, CDR0000657976, MAYO-MC0861, 8329, NCT01012817
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ME-344-002, NCI-2014-01013, NCT02100007
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: V0706, NCI-2014-00478, NCT00601003
Cyclophosphamide, Topotecan Hydrochloride, and Bevacizumab in Treating Patients With Relapsed or Refractory Ewing Sarcoma or Neuroblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: 11-183, NCI-2012-00005, POE10-01, NCT01492673
Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ALDOXORUBICIN-P2-SCLC-01, NCI-2014-02472, NCT02200757
Avatar-Directed Chemotherapy in Treating Patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1463, NCI-2014-02399, Mod14-002986-03, NCT02312245
Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Patients with Small Cell Lung Cancer That Has Relapsed or Not Responded to Treatment
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 508-08, NCI-2009-01308, UNMC-50808, IRB #508-08, NCT00856037
Crizotinib and Combination Chemotherapy in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 21 years
Trial IDs: ADVL1212, NCI-2012-01968, CDR0000734059, COG-ADVL1212, NCT01606878
Sirolimus, Cyclophosphamide, and Topotecan Hydrochloride in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors or Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: CC# 12083, NCI-2012-01942, NCT01670175
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 29
Trial IDs: N2012-01, NCI-2015-00641, P01CA081403, NCT02030964
Simvastatin, Topotecan Hydrochloride, and Cyclophosphamide in Treating Younger Patients with Relapsed and/or Refractory Solid and CNS Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 29
Trial IDs: AFLACST1402, NCI-2015-00420, IRB00078790, NCT02390843
Selinexor with Multiple Standard Chemotherapy Regimens in Treating Patients with Advanced Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0640, NCI-2015-00693, NCT02419495
Risk-Adapted Therapy in Treating Young Children with Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3 at diagnosis
Trial IDs: SJYC07, NCI-2011-01193, SJCRH-SJYC07, NCT00602667
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients with Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy with Isotretinoin
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: ANBL09P1, NCI-2011-01745, CDR0000682629, COG-ANBL09P1, NCT01175356
Topotecan Hydrochloride Using Convection-Enhanced Delivery in Treating Patients with Recurrent High Grade Glioma
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: INFT1314, NCI-2014-02248, INFS 001, NCT02278510
Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: SJRET6, NCI-2013-00409, NCT01783535
Start Over